About:
herontx.com/
|
CRL für Heron´s HTX-011
endpts.com/...o-market-its-long-acting-non-opioid-painkiller/
150 Mio. $ Offering
seekingalpha.com/news/...-therapeutics-prices-equity-offering
FDA weitet den Überprüfungszeitraum für HTX-011 um bis zu 3 Monate aus
herontherapeutics.gcs-web.com/...ension-review-period-nda-htx
CRL für HTX-011
"No Clinical Safety or Efficacy Issues and No Chemistry, Manufacturing and Controls (CMC) Issues Identified "
herontherapeutics.gcs-web.com/...te-response-letter-htx-011-0
dritter Anlauf für HTX-011
www.evaluate.com/vantage/articles/events/...-head-finish-line
FDA Zulassung für Zynrelef
medcitynews.com/2021/05/...al-pain-wins-fda-nod-on-third-try/
Zynrelef
www.fiercepharma.com/pharma/...in-headed-for-blockbuster-land
wie Heron Therapeutics von Biden´s Plänen profitieren könnte
Stichwort: Opioid-Krise
www.fool.com/investing/2021/06/02/...2-little-known-biotechs/
Zahlen für Q2/21
- ZYNRELEF Commercially Launched on July 1, 2021
ir.herontx.com/news-releases/...ncial-results-three-and-six-2
Zahlen für Q3/21
ir.herontx.com/news-releases/...cial-results-three-and-nine-2
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
38 | Heron Therapeutics Announces Phase 3 MAGIC Study | Balu4u | Vassago | 15.11.23 13:03 |